Fig. 1

Evaluation of the clinical importance of EGFR and its correlation with AR in prostate cancer patients. a Immunohistochemical analysis of EGFR expression in primary PCa (n = 17), and in bone, lymph node and lung metastatic PCa sites (n = 43). The TMA staining intensity shows that EGFR protein expression is highest in bone metastatic PCa lesions. b Box plot showed the comparison in EGFR protein expression between primary PCa (n = 17) and metastatic lesions (n = 43) (p = 0.147). c Box plot showed the comparison in EGFR mRNA expression between normal prostate (n = 58), primary PCa (n = 64) and metastatic lesions (n = 24) (p = 0.05). d Gene and mRNA alteration profiles of EGFR and AR in PCa patients (n = 216) where 40% of patients (n = 86) exhibited EGFR alterations on the gene and mRNA level, while 16% of patients (n = 35) exhibited discrepancies in AR gene and mRNA expression. MSKCC Prostate Oncogenome Database was used. e Kaplan-Meier survival curve revealed that patients with alterations in EGFR (n = 70) suffered poorer disease-free survival (DFS) as compared to those without alterations (n = 52), and this difference was statistically significant (p = 0.029). MSKCC Prostate Oncogenome Database was used